Avelumab and Merkel Cell Carcinoma: Causation, Mechanism, and Risk Assessment

From General Health Education to Specialized Exposure Concerns

Legacy health information resources have long served as foundational tools for patient education and clinical guidance, offering accessible overviews of general medical topics such as treatment options for salivary gland disorders, inflammatory conditions, and oral health management. These materials typically present broad, context-neutral summaries that prioritize clarity for diverse audiences, from patients to healthcare providers. Within this framework, discussions of therapeutic interventions—including pharmacological and surgical approaches—remain anchored in established clinical practice, without delving into specific etiological pathways or occupational variables. Transitioning from this general health context to a more specialized domain, the focus narrows to consider how certain pharmaceutical exposures may intersect with occupational environments. Specifically, the biologic agent Avelumab, an immune checkpoint inhibitor used in oncology, introduces a distinct layer of inquiry when its administration occurs in workplace settings. While legacy resources do not typically address drug-induced pathophysiology, the shift toward occupational exposure concern requires examining how Avelumab’s immunomodulatory effects might interact with environmental or occupational co-factors. This pivot reframes the discussion from broad health literacy to a targeted assessment of risk, where the bridge concept lies in recognizing that therapeutic agents, once confined to clinical contexts, can become occupational hazards when handled or administered in professional settings.

Bridge: Avelumab as a Therapeutic Agent and Occupational Hazard

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Merkel cell carcinoma is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment of metastatic MCC is the use of anti-PD-1/-PD-L1 immune checkpoint inhibitors such as avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses in patients (https://pubmed.ncbi.nlm.nih.gov/34445385). Nevertheless, 50% of patients do not respond or develop immune-related adverse events (irAEs) due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385).

Mechanistic Pathway: Avelumab's Role in MCC Pathophysiology

The mechanistic pathway linking avelumab to MCC pathophysiology is not one of causation but rather of therapeutic modulation. Avelumab functions as an immune checkpoint inhibitor, blocking PD-L1 to enhance T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096). In MCC, this can lead to tumor regression, but it can also trigger immune-related adverse events due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). This illustrates that avelumab can induce immune-mediated side effects, but these are distinct from causing MCC itself. Regarding causation-related considerations for affected patients, avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab is an effective therapy for metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). For patients who become refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab have shown activity in avelumab-refractory MCC, with three out of five patients responding according to RECIST 1.1 in a small retrospective study (https://pubmed.ncbi.nlm.nih.gov/33439294). This suggests that avelumab-refractory disease can still be managed with other immune checkpoint inhibitors.

Risk Context: Adverse Events and Occupational Exposure

The timeline between exposure to avelumab and documented harm is relevant to adverse events rather than MCC development. Immune-related adverse events can occur during treatment, as seen in the case of sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781). However, avelumab is not known to trigger MCC pathophysiology; instead, it is used to treat existing MCC. The adequacy of warnings regarding avelumab and MCC should reflect that avelumab is indicated for MCC treatment, and its adverse effects are primarily immune-related, not carcinogenic. The JAVELIN Merkel 200 trial demonstrated efficacy in chemotherapy-refractory patients, supporting its use (https://pubmed.ncbi.nlm.nih.gov/29799096). Warnings should emphasize the risk of immune-related adverse events, which are well-documented in the literature. In summary, avelumab does not cause Merkel cell carcinoma; it is a therapeutic agent approved for treating metastatic MCC. The pathophysiology of MCC involves viral or UV-induced mutations, and avelumab modulates the immune response against tumor cells. Adverse effects are immune-mediated and manageable, with no evidence linking avelumab to triggering MCC. For affected patients, treatment options exist for avelumab-refractory disease, and the timeline for adverse events is during therapy, not preceding MCC diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab does not cause Merkel cell carcinoma. It is a therapeutic agent approved for treating metastatic MCC. The pathophysiology of MCC involves viral or UV-induced mutations, and avelumab modulates the immune response against tumor cells. Adverse effects are immune-mediated and manageable, with no evidence linking avelumab to triggering MCC.

What are the common adverse events associated with avelumab therapy?

Common adverse events include immune-related adverse events such as fatigue, infusion reactions, and immune-mediated conditions like pneumonitis, hepatitis, colitis, and endocrinopathies. A case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient on avelumab, which resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.